Back to today’s briefing

Story perspectives

Immunotherapy Breakthrough: 80% Skip Surgery, Boosts Survival Rates

4/28/2025

35 4

Summary

Immunotherapy Revolutionizes Treatment

Groundbreaking clinical trials are reshaping cancer treatment, showcasing the power of immunotherapy. Remarkably, 80% of patients with mismatch repair-deficient tumors were able to forgo surgery after receiving dostarlimab. Furthermore, pembrolizumab has boosted survival rates for head and neck cancer patients, hinting at a future where immunotherapy could revolutionize care and elevate patient well-being.

Summary

Johnson & Johnson's Breakthrough

Johnson & Johnson's TAR-200 is making waves in bladder cancer treatment, achieving an impressive 82.4% complete response rate in trials. As it competes with ImmunityBio's Anktiva, known for its 45-month median response duration, both companies are vying to broaden their treatment options. J&J highlights TAR-200's convenience, while ImmunityBio prioritizes durability amid BCG shortages.

1 of 2

Immunotherapy Revolutionizes Treatment

Groundbreaking clinical trials are reshaping cancer treatment, showcasing the power of immunotherapy. Remarkably, 80% of patients with mismatch repair-deficient tumors were able to forgo surgery after receiving dostarlimab. Furthermore, pembrolizumab has boosted survival rates for head and neck cancer patients, hinting at a future where immunotherapy could revolutionize care and elevate patient well-being.

1 / 2